卖什么
用AI做整包临床试验。
商业模式拆解
买家：谁掌握预算？
未核实Clinical development, data management, biostatistics, medical writing and regulatory leads at pharma/biotech sponsors, plus R&D heads in materials firms (site routes by role).
触发点：什么让他们现在购买？
Trial design takes about 3 months, traditional CROs stack headcount with data silos, and multi-country filing (Japan especially) is complex while competitors race to market.
工作流：什么输入变成什么输出？
AI CRO 6.0 runs trial protocol design, data capture and QC, statistical analysis and CSR report drafting with AI agents plus human experts, claiming up to 12x faster protocol design and 15x faster medical writing.
经济账：省了什么，怎么收费？
Service-plus-AI CRO model replacing headcount stacking; claims up to 12x faster protocol design (3 months to 1 week), 15x medical writing, 50x monitoring, 10x data management; says commercial loop closed in 2021 with sustained profitability.
渠道：怎么接触到客户？
未核实Direct enterprise sales through contact page, with Chinese, US and Japanese regulatory submission support (3 continents).
融资历史与报道
| 融资日期 | 轮次 | 金额 | 投资方 | 来源 |
|---|---|---|---|---|
| 2025-12-10 | D 轮 | 近5000万美元 | — | m.36kr.com |
档案汇总自公开报道和公司官网。商业模式部分是 MaxBC 对这些材料的解读，不是已确认的事实；未知之处留空，不作猜测。 更新于 2026-10-13.